Q2 2019 Earnings Estimate for Autolus Therapeutics Ltd – (AUTL) Issued By William Blair

Autolus Therapeutics Ltd – (NASDAQ:AUTL) – Research analysts at William Blair decreased their Q2 2019 earnings per share estimates for shares of Autolus Therapeutics in a report issued on Wednesday, May 15th. William Blair analyst M. Phipps now forecasts that the company will post earnings per share of ($0.61) for the quarter, down from their previous forecast of ($0.55). William Blair currently has a “Buy” rating on the stock. William Blair also issued estimates for Autolus Therapeutics’ Q3 2019 earnings at ($0.61) EPS, Q4 2019 earnings at ($0.62) EPS, FY2019 earnings at ($2.53) EPS, Q1 2020 earnings at ($0.63) EPS, Q2 2020 earnings at ($0.64) EPS, Q3 2020 earnings at ($0.65) EPS, Q4 2020 earnings at ($0.67) EPS, FY2020 earnings at ($2.59) EPS, FY2021 earnings at ($3.40) EPS, FY2022 earnings at ($3.51) EPS and FY2023 earnings at ($1.60) EPS.

A number of other analysts have also recently commented on the company. Zacks Investment Research cut Autolus Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday. HC Wainwright began coverage on Autolus Therapeutics in a research report on Friday. They set a “buy” rating and a $41.00 price target for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $42.67.



Shares of AUTL opened at $22.59 on Friday. Autolus Therapeutics has a one year low of $19.17 and a one year high of $53.24. The company has a quick ratio of 15.14, a current ratio of 10.66 and a debt-to-equity ratio of 0.12. The stock has a market cap of $959.49 million and a price-to-earnings ratio of -15.91.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.69) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.11). The business had revenue of $1.96 million during the quarter, compared to the consensus estimate of $0.30 million.

Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. lifted its position in Autolus Therapeutics by 4,011.3% during the 4th quarter. BlackRock Inc. now owns 202,973 shares of the company’s stock worth $6,666,000 after acquiring an additional 198,036 shares during the period. CWM LLC purchased a new position in shares of Autolus Therapeutics during the 1st quarter valued at about $1,105,000. Virtus ETF Advisers LLC purchased a new position in shares of Autolus Therapeutics during the 4th quarter valued at about $312,000. Barclays PLC purchased a new position in shares of Autolus Therapeutics during the 4th quarter valued at about $113,000. Finally, Geode Capital Management LLC purchased a new position in shares of Autolus Therapeutics during the 4th quarter valued at about $322,000. 40.63% of the stock is owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.

Featured Story: How to identify percentage decliners

Earnings History and Estimates for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.